ERBB2 and neoplasm: T-DM1 was the first FDA approved ADC for use in HER2-enriched tumours, and consists of trastuzumab conjugated to a naturally occurring microtubule polymerization inhibitor, emtansine (Peddi and Hurvitz, 2014).